Champix

RSS

varenicline

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Champix. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Champix.

This EPAR was last updated on 18/10/2021

Authorisation details

Product details
Name
Champix
Agency product number
EMEA/H/C/000699
Active substance
varenicline
International non-proprietary name (INN) or common name
varenicline
Therapeutic area (MeSH)
Tobacco Use Cessation
Anatomical therapeutic chemical (ATC) code
N07BA03
Publication details
Marketing-authorisation holder
Pfizer Europe MA EEIG
Revision
37
Date of issue of marketing authorisation valid throughout the European Union
25/09/2006
Contact address

Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Product information

21/09/2021 Champix - EMEA/H/C/000699 - N/0081

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other nervous system drugs

Therapeutic indication

Champix is indicated for smoking cessation in adults.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings
2 ratings
2 ratings